BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...
FierceBiotech5d
BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
BioAge seeks nearly $200 million in initial public offering
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
MedCity News5d
Exercise Benefit in a Pill: BioAge Labs Goes Public, Raising More Than $200M for Clinical Trials
BioAge Labs aims to help those medications work better with a lead drug candidate envisioned as a part of new GLP-1 combination therapies. With a key clinical trial already underway, BioAge has ...
BioAge Labs Announces Pricing of Upsized Initial Public Offering
BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of ...
Ryan Reynolds's MNTN Explores Going Public, as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...